Voyager and Exobiosphere Will Expand ISS Biotech Research
New research campaigns will launch later this year to test automated drug screening in microgravity.
Updated on Sept. 24, 2026 in Biotech
Live Poll
Do you believe pharmaceutical companies should invest in drug research conducted on orbital space platforms?
Voyager Technologies and Exobiosphere have secured two additional research campaigns aboard the International Space Station, starting in June 2027. The project aims to transition commercial biotech research in microgravity into a routine, schedulable service.
Why it matters
By establishing recurring research cycles, the companies are working to prove that microgravity environments can support predictable, industrial-scale biotechnology investigations rather than one-off experiments.
The Exobiosphere OHTS platform utilizes standardized well plates to conduct automated drug screening. The system is designed to facilitate the exchange of samples, test compounds, and consumables between individual campaigns to accommodate evolving scientific objectives.
The players
Voyager Technologies
This company provides aerospace solutions and manages mission-critical infrastructure for commercial research.
Exobiosphere
This biotechnology firm specializes in developing automated hardware platforms for experiments in microgravity.
The details
Voyager Europe will oversee mission management and provisioning, while Voyager Space Solutions manages payload processing and pre-flight preparations at a Houston-based facility. The collaboration leverages these operational teams to ensure the automated screening technology remains functional and adaptive for subsequent flights.
Timeline
The OHTS drug-screening platform is scheduled for installation on the International Space Station in April 2027.
The first of the two newly added research campaigns is slated to launch in June 2027.
The second research campaign is scheduled to take place during the August-September 2027 timeframe.
The Tech Race
This move marks a departure from traditional, manually intensive space experiments toward an automated, modular approach to off-planet research. It positions these firms as leaders in the emerging market for sustainable, recurring biotech operations in low-Earth orbit.
For researchers and pharmaceutical developers, this transition to a recurring service model could significantly reduce the time and cost required to access microgravity for high-stakes drug screening. Successful industrialization of these processes may eventually lead to more efficient drug discovery and development cycles for medicines used on Earth.
The takeaway
The transition toward schedulable biotech missions signifies a major step in making space a viable lab for commercial industry. Scientists looking to innovate should monitor how these automated systems handle different compounds to assess potential utility for their own drug-screening workflows.
What happens next
The OHTS platform is set for installation on the International Space Station in April 2027, followed by the first research campaign launch in June 2027 and a second campaign in the August-September 2027 window.
Further reading
For more on the latest developments in space-based medical studies, visit our Biotech section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you believe pharmaceutical companies should invest in drug research conducted on orbital space platforms?
